Results 331 to 340 of about 383,810 (341)

VEGF: A modifier of the del22q11 (DiGeorge) syndrome?

Nature Medicine, 2003
Hemizygous deletion of chromosome 22q11 (del22q11) causes thymic, parathyroid, craniofacial and life-threatening cardiovascular birth defects in 1 in 4,000 infants. The del22q11 syndrome is likely caused by haploinsufficiency of TBX1, but its variable expressivity indicates the involvement of additional modifiers.
Ingeborg, Stalmans, Diether, Lambrechts, Frederik, De Smet, Sandra, Jansen, Jian, Wang, Sunit, Maity, Paige, Kneer, Maren, von der Ohe, Ann, Swillen, Christa, Maes, Marc, Gewillig, Daniel G M, Molin, Peter, Hellings, Thurid, Boetel, Maartin, Haardt, Veerle, Compernolle, Mieke, Dewerchin, Stephane, Plaisance, Robert, Vlietinck, Beverly, Emanuel, Adriana C, Gittenberger-de Groot, Peter, Scambler, Bernice, Morrow, Deborah A, Driscol, Lieve, Moons, Camila V, Esguerra, Geert, Carmeliet, Annett, Behn-Krappa, Koen, Devriendt, Désiré, Collen, Simon J, Conway, Peter, Carmeliet   +31 more
openaire   +2 more sources

VEGF-A and the Induction of Pathological Angiogenesis

Annual Review of Pathology: Mechanisms of Disease, 2007
Tumors, wounds, and chronic inflammatory disorders generate a new vascular supply by a process known as pathological angiogenesis. Whereas formation of the normal blood vasculature requires the interaction of many different agonists and inhibitors, including vascular endothelial growth factor-A (VEGF-A) and other members of the vascular permeability ...
Janice A, Nagy, Ann M, Dvorak, Harold F, Dvorak   +2 more
openaire   +2 more sources

Die Zukunft der Anti-VEGF-A-Therapie

Kompass Ophthalmologie, 2021
Anti-vascular endothelial growth factors (anti-VEGF) have become the most common treatment modality for many retinal diseases. These include neovascular age-related macular degeneration (n-AMD), proliferative diabetic retinopathy (PDR) and retinal vein occlusions (RVO).
openaire   +1 more source

Post-transcriptional Regulation of VEGF-A

2015
Vascular Endothelial Growth Factor A (VEGF-A) is a secreted growth and survival factor that binds to endothelial cells and plays a critical role in the induction of angiogenic processes. It is essential for embryonic development and during adulthood plays a key role in physiological processes that require angiogenesis, such as the growth and ...
Hervé Prats, Christian Touriol
openaire   +1 more source

Neues von der Anti-VEGF-A-Therapie

Kompass Ophthalmologie, 2023
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have been increasingly applied in the treatment of retinal neovascular diseases. Concerns have arisen that these intravitreal agents may be associated with a potential risk of arterial thromboembolic (ATE) events.
openaire   +1 more source

Lymphangiogenesis in the developing lung promoted by VEGF-A

Microvascular Research, 2006
Understanding the basic processes of late-stage pulmonary vascular development is essential as this period corresponds to the stage when preterm infants have increased chance of survival. During this period, refinement of the gas exchange unit leads to close apposition of the capillary vasculature and airway epithelium through thinning of the ...
Bradford P, Mallory, Timothy J, Mead, Diane A F, Wiginton, Rishikesh M, Kulkarni, James M, Greenberg, Ann L, Akeson   +5 more
openaire   +2 more sources

Novel VEGF-A ELISA allows sensitive quantification of human total bioactive VEGF-A

Osteologie, 2020
G Berg, Andreea Ana-Maria Suciu, E Gadermaier, J Wallwitz, G Himmler   +4 more
openaire   +1 more source

VEGF-A

2018
openaire   +1 more source

VEGF-A isoforms, pro-angiogenic, anti-angiogenic

2021
openaire   +1 more source

Die Rolle von VEGF-A im Alkoholentzug

Suchttherapie, 2009
openaire   +1 more source